Melissa Coffel

Melissa Coffel

Auto-generated profile, based on publicly available information

Melissa Coffel

School of Nursing, University of North Carolina, Chapel Hill, NC, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in JMIR Cancer
Verified
Journal Article
Open access
SKSaif Khairat
Saif Khairat
HMHanna Mehraby
Hanna Mehraby
SMSafoora Masoumi
Safoora Masoumi
MCMelissa Coffel
Melissa Coffel
CRCallie Rockey-Bartlett
Callie Rockey-Bartlett
EBEthan Basch
Ethan Basch
Background: Cancer survivorship is a complicated, chronic, and long-lasting experience, causing uncertainty and a wide range of physical and emotional health concerns. Due to the complexity of cancer, patients often seek out multiple sources of health information to better understand the aspects of their cancer diagnosis. The high variability among patients with cancer presents significant challenges in treatment, prognosis, and overall disease management. Artificial intelligence (AI) chatbots can further personalize cancer care delivery. However, there is a knowledge gap regarding cancer survivors’ perceived facilitators and barriers to adopting and using AI chatbots. Objective: In this study, we examined cancer survivors’ experiences of using existing AI chatbots and identified their facilitators and barriers to the adoption of AI chatbots. Methods: We conducted a qualitative study to investigate the perceptions of cancer survivors, conducting semistructured interviews to understand their prior use of existing AI chatbots in general. We asked the participants about their perceptions regarding AI chatbot acceptability and comfort level; trust and adherence; and concerns, barriers, and suggestions. We used the Consolidated Criteria for Reporting Qualitative Research (COREQ) checklist for this qualitative report. Results: Of 21 participants, 17 (81%) were female patients with breast cancer, 15 (71%) were aged 50 to 64 years, 19 (90%) were White, and 9 (43%) had a graduate degree. Participants’ responses were grouped into three overarching themes: (1) patients’ perceptions of interacting with chatbots compared to health care professionals, (2) patient-chatbot interaction, and (3) chatbot information processing. All participants who were interviewed reported that they would prefer interacting with health care professionals over a chatbot. The lack of empathy shown by chatbots was a major concern among cancer survivors. Many patients criticized chatbots for tending to provide a general overarching response to their questions rather than being specific to their cancer diagnosis. The main concerns of cancer survivors with using chatbots were the overabundance of general information that was often not relevant to their diagnosis and privacy of patient information. Conclusions: The findings of this study underscore the critical importance of empathetic responses during AI chatbot interactions for cancer survivors, as the lack of personalized and emotional responses can lead to distrust and frustration. Clinically, these tools should be integrated as supplementary resources to enhance patient engagement while preserving essential human support. Policymakers need to develop guidelines that promote responsible use of AI in cancer care, prioritizing patient confidentiality and trustworthiness. AI chatbots have the potential to significantly improve the support provided to cancer survivors, but it is crucial to address the identified barriers and enhance user acceptance.

1 May 2025 in Digital Health
Verified
Journal Article
Open access
CRCallie Rockey-Bartlett
Callie Rockey-Bartlett
JMJennifer Morelli
Jennifer Morelli
MCMelissa Coffel
Melissa Coffel
JGJohn Geracitano
John Geracitano
JLJennifer A. Elston Lafata
Jennifer A. Elston Lafata
SKSaif Khairat
Saif Khairat
Purpose: Remote patient monitoring (RPM) allows healthcare providers to monitor patient outcomes outside of a traditional healthcare setting, potentially supporting reductions in acute care utilization. This systematic review aims to assess whether RPM use among cancer patients reduces hospitalizations and length of stay (LOS). Methods: A systematic review was conducted to identify articles published in PubMed and CINAHL between 2019 and 2024 that evaluated the impacts of RPM in cancer patients compared to the standard care. The primary outcomes examined were hospitalizations and LOS. Secondary outcomes were emergency department (ED) visits and hospital readmissions. Two reviewers screened and assessed the studies. Evidence strength was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach. Risk of bias was assessed using the Newcastle-Ottawa Scale and the Cochrane risk-of-bias tool for randomized trials (RoB 2). While statistical tests were not conducted on results, outcomes were categorized as having increased, decreased, or no change. Results: This review included one randomized controlled trial, seven cohort studies, and one case-control study. RPM was associated with reductions in healthcare utilization among cancer patients. There were significant reductions in hospitalizations, LOS, ED visits, and hospital readmissions in 67% (4/6), 67% (4/6), 75% (3/4), and 67% (2/3) of studies, respectively. Conclusion: This systematic review builds upon existing literature that demonstrates the effectiveness of using RPM to manage acute conditions such as cancer. RPM may support management of various cancer-related conditions and, in turn, potentially reduce acute care use. However, study homogeneity and additional rigorous study designs are necessary to draw more definitive conclusions about the impacts of RPM in cancer care.

26 September 2025 in Journal of Patient Experience
Verified
Journal Article
Open access
PCPrabal Chourasia
Prabal Chourasia
MCMelissa Coffel
Melissa Coffel
JCJamie Conklin
Jamie Conklin
WWWilliam A. Wood
William A. Wood
SKSaif Khairat
Saif Khairat
With artificial intelligence (AI) on the rise in healthcare, we investigated the acceptance and adoption of AI among cancer survivors who are seeking information. We searched 3 databases—PubMed, Scopus, and CINAHL for original research studies examining cancer survivors’ acceptance and adoption of AI while seeking information. We screened 858 articles, resulting in the inclusion of 12 studies. Cancer survivors’ perceived benefits of AI include diagnostic accuracy, improved healthcare access, and reduced healthcare costs. Concerns included the loss of human interaction, data loss, and privacy issues. Adoption and acceptance of AI-based Chatbots and cancer trial search tools were also demonstrated. Regarding the ethical use of AI, cancer survivors shared a desire for data de-identification, disclosure, and transparency. Cancer survivors accepted AI as an adjunct to physicians. Patients demonstrated acceptance and adoption of both AI-based educational tools and search engines. Developing AI models with better explainability and education can improve cancer survivors’ acceptance and adoption of AI.